| | 7481-89-2 Basic information More.. |
| Product Name: | Zalcitabine | | Synonyms: | 4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]PYRIMIDIN-2-ONE;ZALCITABINE;1-(2',3'-DIDEOXY-BETA-RIBOFURANOSYL)CYTOSINE;2',3'-Dideoxy-D-cytidine;2'',3''-DIDEOXYCYTIDINE(ZALCITABINE);Cytidine, 2',3'-dideoxy- (8CI, 9CI);D 2C;NSC 606170 | | CAS: | 7481-89-2 | | MF: | C9H13N3O3 | | MW: | 211.22 | | EINECS: | 620-762-3 | | Mol File: | 7481-89-2.mol |  |
Use
Zalcitabine, 2',3'-dideoxycytidine or ddCyd, is an analog ofcytosine that demonstrates activity against HIV-1 and HIV-2,including strains resistant to AZT. The potency (in peripheralblood mononuclear cells) is similar to that of AZT, but thedrug is more active in populations of monocytes andmacrophages as well as in resting cells.The oral bioavailability of zalcitabine is over 80% in adultsand less in children.The major dose-limiting side effect isperipheral neuropathy, characterized by pain, paresthesias,and hypesthesia, beginning in the distal lower extremities.These side effects are typically evident after several months oftherapy with zalcitabine. A potentially fatal pancreatitis is anothertoxic effect of treatment with ddC. The drug has beenapproved for the treatment of HIV infection in adults with advanceddisease who are intolerant to AZT or who have diseaseprogression while receiving AZT. ddC is combined with AZTfor the treatment of advanced HIV infection.
- Zalcitabine
-
- US $30.00-61.00 / mg
- 2024-11-09
- CAS:7481-89-2
- Min. Order:
- Purity: ≥95%
- Supply Ability: 10g
- Zalcitabine
-
- US $30.00-61.00 / mg
- 2024-11-08
- CAS:7481-89-2
- Min. Order:
- Purity: ≥95%
- Supply Ability: 10g
- Zalcitabine
-
- US $30.00 / kg
- 2024-11-08
- CAS:7481-89-2
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 3000kg
|
|
7481-89-2
Recommend Suppliers |
|